Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients

医学 氯吡格雷 急性冠脉综合征 内科学 P2Y12 降级 心肌梗塞 心脏病学
作者
Jaouad Azzahhafi,Wout W. A. van den Broek,Dean R.P.P. Chan Pin Yin,Niels M R van der Sangen,S. Sivanesan,Salahodin Bofarid,Joyce Peper,Daniel M.F. Claassens,Paul W.A. Janssen,Ankie M. Harmsze,Ronald J Walhout,Melvyn Tjon Joe Gin,Deborah M. Nicastia,Jorina Langerveld,Georgios J. Vlachojannis,Rutger J. van Bommel,Yolande Appelman,Ron H. N. van Schaik,José P.S. Henriques,Wouter J. Kikkert
出处
期刊:Jacc-cardiovascular Interventions [Elsevier BV]
卷期号:17 (17): 1996-2007 被引量:3
标识
DOI:10.1016/j.jcin.2024.06.020
摘要

CYP2C19 genotype–guided de-escalation from ticagrelor or prasugrel to clopidogrel may optimize the balance between ischemic and bleeding risk in patients with acute coronary syndrome (ACS). This study sought to compare bleeding and ischemic event rates in genotyped patients vs standard care. Since 2015, ACS patients in the multicenter FORCE-ACS (Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome) registry received standard dual antiplatelet therapy (DAPT). Since 2021, genotype-guided P2Y12 inhibitor de-escalation was recommended at a single center, switching noncarriers of the loss-of-function allele CYP2C19∗3 or CYP2C19∗2 from ticagrelor or prasugrel to clopidogrel, whereas loss-of-function carriers remained on ticagrelor or prasugrel. The primary ischemic endpoint, a composite of cardiovascular mortality, myocardial infarction, or stroke, and the primary bleeding endpoint, Bleeding Academic Research Consortium 2, 3, or 5 bleeding, were compared between a genotyped cohort and a cohort treated with standard DAPT after 1 year. Among 5,321 enrolled ACS patients, 406 underwent genotyping compared with 4,915 nongenotyped ACS patients on standard DAPT. In the genotyped cohort, 65.3% (n = 265) were noncarriers, 88.7% (n = 235) of whom were switched to clopidogrel. The primary ischemic endpoint occurred in 5.2% (n = 21) of patients in the genotyped cohort compared to 6.9% (n = 337) in the standard care cohort (adjusted HR: 0.82; 95% CI: 0.53-1.28). The primary bleeding rate was significantly lower in the genotyped cohort compared to the standard care cohort (4.7% vs 9.8%; adjusted HR: 0.47; 95% CI: 0.30-0.76). The implementation of a CYP2C19 genotype–guided P2Y12 inhibitor de-escalation strategy in a real-world ACS population resulted in lower bleeding rates without an increase in ischemic events compared to a standard DAPT regimen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
ZnGaLi发布了新的文献求助20
1秒前
2秒前
orixero的应助被hjygzv采纳,获得10
2秒前
什米完成签到,获得积分10
2秒前
2秒前
范梦丽发布了新的文献求助10
2秒前
2秒前
失眠代秋完成签到 ,获得积分10
3秒前
Zz发布了新的文献求助10
3秒前
Regn完成签到,获得积分10
3秒前
李健的应助被yi采纳,获得10
3秒前
zhoujin完成签到,获得积分20
3秒前
4秒前
4秒前
4秒前
4秒前
汉堡包的应助被九月初采纳,获得10
4秒前
安详晓亦发布了新的文献求助10
5秒前
liujiaqi完成签到,获得积分10
5秒前
谦让秋白完成签到,获得积分10
5秒前
5秒前
5秒前
咕_完成签到 ,获得积分10
5秒前
5秒前
6秒前
微笑的海蓝完成签到 ,获得积分10
6秒前
萝卜仙儿完成签到,获得积分10
6秒前
7秒前
哈哈哈完成签到,获得积分10
7秒前
7秒前
7秒前
科研通AI6.4的应助被飞快的孱采纳,获得10
7秒前
高高完成签到,获得积分10
8秒前
老苍发布了新的文献求助10
8秒前
白蓝发布了新的文献求助10
8秒前
苏波关注了科研通微信公众号
8秒前
奋斗信封发布了新的文献求助10
8秒前
orixero的应助被zhoujin采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183046
求助须知:如何正确求助?哪些是违规求助? 9572370
关于积分的说明 21824411
捐赠科研通 7779694
什么是DOI,文献DOI怎么找? 3433792
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971